Holen Sie sich die Stockscreener-App
72.64
0.01%
0.01
Handel nachbörslich:
72.64
Schlusskurs vom Vortag:
$72.63
Offen:
$72.64
24-Stunden-Volumen:
494.19K
Relative Volume:
0.11
Marktkapitalisierung:
$10.95B
Einnahmen:
$10.73M
Nettoeinkommen (Verlust:
$-455.74M
KGV:
-20.42
EPS:
-3.5569
Netto-Cashflow:
$-502.70M
1W Leistung:
+0.23%
1M Leistung:
+0.71%
6M Leistung:
+100.28%
1J Leistung:
+138.63%
1-Tages-Spanne:
$72.56
$72.66
1-Wochen-Bereich:
$72.45
$72.74
52-Wochen-Spanne:
$21.51
$72.74
Avidity Biosciences Inc Stock (RNA) Company Profile
Firmenname
Avidity Biosciences Inc
Sektor
Branche
Telefon
858-401-7900
Adresse
3020 CALLAN ROAD, SAN DIEGO, CA
Vergleichen Sie RNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
72.64 | 10.94B | 10.73M | -455.74M | -502.70M | -3.5569 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Eingeleitet | Roth Capital | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-06-24 | Eingeleitet | Bernstein | Outperform |
| 2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
| 2025-06-11 | Eingeleitet | Raymond James | Strong Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-09-24 | Eingeleitet | Goldman | Buy |
| 2024-08-28 | Eingeleitet | Barclays | Overweight |
| 2024-05-03 | Eingeleitet | BofA Securities | Buy |
| 2024-03-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-05-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Strong Buy |
| 2021-09-07 | Eingeleitet | Evercore ISI | Outperform |
| 2021-06-17 | Eingeleitet | Needham | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-07-07 | Eingeleitet | Cowen | Outperform |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-07-07 | Eingeleitet | SVB Leerink | Outperform |
| 2020-07-07 | Eingeleitet | Wells Fargo | Overweight |
Alle ansehen
Avidity Biosciences Inc Aktie (RNA) Neueste Nachrichten
EFG Asset Management North America Corp. Reduces Holdings in Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences, Inc. (RNA) Stock Analysis: A Biotech Powerhouse with 434% Revenue Growth and Promising Clinical Trials - directorstalkinterviews.com
Aug Momentum: Will Avidity Biosciences Inc outperform tech stocksJuly 2025 Review & Stepwise Trade Execution Plans - baoquankhu1.vn
Avidity Biosciences CSO sells $473k in RNA stock By Investing.com - Investing.com South Africa
Avidity Biosciences CFO MacLean sells $329k in stock By Investing.com - Investing.com Australia
Avidity Biosciences CMO sells $354k in stock By Investing.com - Investing.com South Africa
Avidity Biosciences Insider Sold Shares Worth $473,388, According to a Recent SEC Filing - 富途资讯
Avidity Biosciences CEO Boyce sells $1.04 million in stock By Investing.com - Investing.com Canada
Avidity Biosciences (NASDAQ:RNA) Insider Sells $473,388.30 in Stock - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Insider Sells $354,642.75 in Stock - MarketBeat
Avidity Biosciences (NASDAQ:RNA) CEO Sells $1,042,338.15 in Stock - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Insider Teresa Mccarthy Sells 2,929 Shares - MarketBeat
Avidity Biosciences CMO sells $354k in stock - Investing.com
Avidity Biosciences CSO sells $473k in RNA stock - Investing.com
Avidity Biosciences stock hits all-time high at $72.70 By Investing.com - Investing.com Nigeria
Avidity Biosciences (NASDAQ:RNA) Reaches New 12-Month HighHere's What Happened - MarketBeat
Avidity Biosciences stock hits all-time high at $72.70 - Investing.com
Weekly Earnings: Can Kosmos Energy Ltd expand into new marketsQuarterly Performance Summary & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Retail Trends: Is Avidity Biosciences Inc a cyclical or defensive stockJuly 2025 Rallies & Low Volatility Stock Recommendations - baoquankhu1.vn
Avidity reports FTC granted request for early termination of HSR waiting period - MSN
Avidity Biosciences, Inc. (RNA) Stock Analysis: Exploring the Biotech Firm’s 434% Revenue Growth and Future Prospects - directorstalkinterviews.com
Avidity Biosciences CFO sells $93,985 in stock - MSN
Can Avidity Biosciences Inc continue delivering strong returnsTrade Ideas & Pattern Based Trade Signal System - baoquankhu1.vn
Aug PostEarnings: Can Avidity Biosciences Inc outperform in the next rallyJuly 2025 Volume & AI Driven Stock Price Forecasts - baoquankhu1.vn
Avidity Biosciences (NASDAQ:RNA) Hits New 1-Year HighHere's What Happened - MarketBeat
Avidity Biosciences stock hits all-time high at 72.63 USD By Investing.com - Investing.com India
Avidity Biosciences stock hits all-time high at 72.63 USD - Investing.com
Novartis (NYSE: NVS) details Avidity deal and Atrium SpinCo plans - Stock Titan
Understanding the Setup: (RNA) and Scalable Risk - Stock Traders Daily
Hedge Fund Moves: Can Avidity Biosciences Inc. stock sustain free cash flow growthMarket Trend Review & Real-Time Buy Signal Alerts - moha.gov.vn
Earnings Beat: Will Avidity Biosciences Inc outperform tech stocksJuly 2025 Levels & Fast Moving Trade Plans - baoquankhu1.vn
Avidity Biosciences, Inc. (RNA) Stock Analysis: Impressive Revenue Growth Amidst Biotech Sector Challenges - DirectorsTalk Interviews
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Insider Selling: Avidity Biosciences (NASDAQ:RNA) CEO Sells 8,576 Shares of Stock - MarketBeat
Insider Selling: Avidity Biosciences (NASDAQ:RNA) Insider Sells 2,374 Shares of Stock - MarketBeat
Charles Calderaro III Sells 3,727 Shares of Avidity Biosciences (NASDAQ:RNA) Stock - MarketBeat
Novartis to acquire Avidity Biosciences for about $12B - MSN
Insider Selling: Avidity Biosciences (NASDAQ:RNA) Insider Sells 1,965 Shares of Stock - MarketBeat
Why Avidity Biosciences Inc. stock attracts high net worth investors2025 Historical Comparison & Free Fast Entry Momentum Trade Alerts - ulpravda.ru
Will Avidity Biosciences Inc. stock gain from strong economyOil Prices & Free Verified High Yield Trade Plans - ulpravda.ru
Avidity Biosciences (NASDAQ:RNA) Stock Crosses Above Fifty Day Moving AverageHere's Why - MarketBeat
Avidity Biosciences, Inc. (RNA) Stock Analysis: Navigating a 434% Revenue Surge and Strategic Clinical Trials - DirectorsTalk Interviews
Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James - MSN
The Technical Signals Behind (RNA) That Institutions Follow - Stock Traders Daily
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates - sharewise.com
Is Avidity Biosciences Inc a good long term investmentStock Price Divergence & Market Monitoring and Alerts - earlytimes.in
Avidity Biosciences Earnings Notes - Trefis
Is Avidity Biosciences Inc. stock resilient to inflationSupport Zone Identification & High Return Trading Ideas - bollywoodhelpline.com
Avidity Biosciences, Inc. (RNA) Stock Analysis: Navigating a 434% Revenue Surge and Potential 3.47% Upside - DirectorsTalk Interviews
CEO Moves: Is Avidity Biosciences Inc stock a buy on dipsSwing Trade & Weekly High Return Opportunities - moha.gov.vn
Novartis to acquire Avidity Biosciences for about $12 billion - MSN
Finanzdaten der Avidity Biosciences Inc-Aktie (RNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):